Mary R Cahill

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3187774/publications.pdf

Version: 2024-02-01

	567281	552781
704	15	26
citations	h-index	g-index
4-	4.5	0.400
45	45	3432
docs citations	times ranked	citing authors
	45	704 15 citations h-index 45 45

#	Article	IF	CITATIONS
1	Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2022, 97, 562-573.	4.1	3
2	All-Trans-Retinoic Acid Combined With Valproic Acid Can Promote Differentiation in Myeloid Leukemia Cells by an Autophagy Dependent Mechanism. Frontiers in Oncology, 2022, 12, 848517.	2.8	3
3	Functional impairment of erythropoiesis in Congenital Dyserythropoietic Anaemia type I arises at the progenitor level. British Journal of Haematology, 2022, , .	2.5	O
4	Platelet hyperactivation in multiple myeloma is also evident in patients with premalignant monoclonal gammopathy of undetermined significance. British Journal of Haematology, 2021, 192, 322-332.	2.5	9
5	Can absolute basophilia distinguish e1a2 BCR-ABL1 chronic myeloid leukemia from chronic myelomonocytic leukemia?. Blood Cells, Molecules, and Diseases, 2021, 87, 102521.	1.4	2
6	Polycythemia vera emerging eighteen years after acute myeloid leukemia diagnosis. Blood Research, 2021, 56, 121-123.	1.3	1
7	Platelet hyperactivation and hyporesponsiveness at diagnosis in multiple myeloma persists during treatment initiation. Thrombosis Research, 2021, 203, 186-189.	1.7	O
8	The Importance of Alpha-Actinin Proteins in Platelet Formation and Function, and Their Causative Role in Congenital Macrothrombocytopenia. International Journal of Molecular Sciences, 2021, 22, 9363.	4.1	5
9	Examining the Usefulness of the Charlson Comorbidity Index to Predict Early Mortality in Patients with Acute Myeloid Leukaemia. Blood, 2021, 138, 1218-1218.	1.4	O
10	Educational intervention to optimise serum immunoglobulin test use in Irish primary care: an interrupted time series with segmented regression analysis. British Journal of General Practice, 2020, 70, e146-e154.	1.4	2
11	Allâ€∢i>trans retinoic acid (ATRA)â€induced <i>TFEB</i> expression is required for myeloid differentiation in acute promyelocytic leukemia (APL). European Journal of Haematology, 2020, 104, 236-250.	2.2	21
12	Inhibition of UBE2L6 attenuates ISGylation and impedes ATRAâ€induced differentiation of leukemic cells. Molecular Oncology, 2020, 14, 1297-1309.	4.6	15
13	Theranostic drug test incorporating the boneâ€marrow microenvironment can predict the clinical response of acute myeloid leukaemia to chemotherapy. British Journal of Haematology, 2020, 189, e254-e258.	2.5	4
14	Physician and practice characteristics associated with immunoglobulin test ordering. Family Practice, 2018, 35, 41-46.	1.9	3
15	Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG) Tj ETQq1 abbreviated frontline therapy with FCR in non-del(17p) CLL. Leukemia and Lymphoma, 2018, 59, 1338-1347.	1 0.7843 1.3	14 rgBT /Ov 7
16	The potential for clinical translation of antibody-targeted nanoparticles in the treatment of acute myeloid leukaemia. Journal of Controlled Release, 2018, 286, 154-166.	9.9	19
17	Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study. Blood, 2018, 132, 3242-3242.	1.4	0
18	Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, <i>in Vitro</i> Mechanistic Studies, and <i>ex Vivo</i> Patient Derived Therapeutic Efficacy. Molecular Pharmaceutics, 2017, 14, 940-952.	4.6	56

#	Article	IF	CITATIONS
19	CALR mutation profile in Irish patients with myeloproliferative neoplasms. Hematology/ Oncology and Stem Cell Therapy, 2016, 9, 112-115.	0.9	0
20	A novel 33â€Gene targeted resequencing panel provides accurate, clinicalâ€grade diagnosis and improves patient management for rare inherited anaemias. British Journal of Haematology, 2016, 175, 318-330.	2.5	72
21	RNA interference for multiple myeloma therapy: targeting signal transduction pathways. Expert Opinion on Therapeutic Targets, 2016, 20, 107-121.	3.4	16
22	Minimal Residual Disease (MRD) Status in FCR-Treated CLL Patients at the End of Treatment Influences Progression Free Survival (PFS), Results of the Ctrial-IE (ICORG) 07-01/ CLL Ireland Study, with Mutational Analysis Providing Additional Insight. Blood, 2016, 128, 3237-3237.	1.4	1
23	The effectiveness of interventions to improve laboratory requesting patterns among primary care physicians: a systematic review. Implementation Science, 2015, 10, 167.	6.9	45
24	Smoking as an independent risk factor for macrocytosis in middleâ€aged adults: A populationâ€based observational study. American Journal of Hematology, 2015, 90, E196-7.	4.1	3
25	Induction of autophagy is a key component of all-trans-retinoic acid-induced differentiation in leukemia cells and a potential target for pharmacologic modulation. Experimental Hematology, 2015, 43, 781-793.e2.	0.4	49
26	Biomimetic nanoparticles for siRNA delivery in the treatment of leukaemia. Biotechnology Advances, 2014, 32, 1396-1409.	11.7	38
27	Retinoid receptor signaling and autophagy in acute promyelocytic leukemia. Experimental Cell Research, 2014, 324, 1-12.	2.6	37
28	Regulation of Trib2 by an E2F1-C/EBPÎ \pm feedback loop in AML cell proliferation. Blood, 2014, 123, 2389-2400.	1.4	44
29	ATRA-Induced Activation of the Autophagy Regulator Tfeb Regulates Myeloid Differentiation in Acute Promyelocytic Leukemia. Blood, 2014, 124, 1057-1057.	1.4	0
30	A multiâ€centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia. British Journal of Haematology, 2013, 163, 118-122.	2.5	50
31	Induction of autophagy by Imatinib sequesters Bcrâ€Abl in autophagosomes and downâ€regulates Bcrâ€Abl protein. American Journal of Hematology, 2013, 88, 455-462.	4.1	45
32	Haematinic Deficiency and Macrocytosis in Middle-Aged and Older Adults. PLoS ONE, 2013, 8, e77743.	2.5	18
33	Cigarette Smoking Is An Under Recognised Cause Of Macrocytosis. Blood, 2013, 122, 4660-4660.	1.4	3
34	Irish Hospitals Meet Proposed International Guidelines For Non-Hodgkin Lymphoma Management, But Areas For Improvement Remain. Blood, 2013, 122, 5591-5591.	1.4	0
35	Macrocytosis: A Metabolic Marker?. Blood, 2013, 122, 4663-4663.	1.4	0
36	Radiation Exposure From Diagnostic Imaging in Patients with Lymphoma - The Cost Of The Cure?. Blood, 2013, 122, 557-557.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Elucidation and Therapeutic Targeting Of The Molecular Mechanism Of TRIB2-Mediated Acute Myeloid Leukaemia. Blood, 2013, 122, 3799-3799.	1.4	0
38	Autophagy As a Target for Differentiation Therapy in Acute Myeloid Leukemia Blood, 2012, 120, 2464-2464.	1.4	2
39	Sustained clinical remission despite suboptimal molecular response to imatinib in e1a2 BCR–ABL chronic myeloid leukemia. Leukemia Research, 2010, 34, e176-e177.	0.8	0
40	The Novel Orally Active Aurora A Kinase Inhibitor MLN8237 Is Highly Active in Preclinical Models of Acute Myeloid Leukemia and Significantly Increases the Efficacy of Cytarabine Blood, 2009, 114, 2087-2087.	1.4	5
41	Phase 1 Clinical Trial of Prion-Filtered Red Cell Concentrates (pfRCC) in Patients Requiring Allogeneic Blood Transfusion Blood, 2008, 112, 994-994.	1.4	0
42	Writing to patients: a randomised controlled trial. Clinical Medicine, 2006, 6, 178-182.	1.9	22
43	Duration of increased bleeding tendency after cessation of aspirin therapy. Journal of the American College of Surgeons, 2005, 200, 564-573.	0.5	68
44	Detection of Aspirin Resistance by PFA-100: Prevalence and Aspirin Compliance in Patients with Chronic Stable Angina. Seminars in Thrombosis and Hemostasis, 2005, 31, 420-425.	2.7	13
45	Adhesion Molecules in Clinical Medicine. Critical Reviews in Clinical Laboratory Sciences, 1998, 35, 415-459.	6.1	23